KPRX revenueQ4 2025$0
- FY YoY
- -100.0%
KPRX revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), compared with $0 a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
Kiora Pharmaceuticals Inc. (KPRX) financials
For fiscal 2025 (ended Dec 31, 2025), Kiora Pharmaceuticals Inc. reported $0 of revenue and -$10.84M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$10.84M
- Free cash flow, FY2025
- -$10.07M
- EPS, diluted, FY2025
- -$2.64
- Cash
- $7.08M
- Market cap
- $6.1M
FY2016FY2025
FY2016FY2025
FY2016FY2025
KPRX revenue and earnings growth
KPRX net incomeQ2 2026-$2.08M
KPRX net income was -$2.08M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.15M a year earlier. For the full fiscal 2025 it was -$10.84M, compared with $3.59M in fiscal 2024.
KPRX EPSQ2 2026-$0.34
KPRX diluted EPS was -$0.34 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$2.64, compared with $0.87 in fiscal 2024.
KPRX free cash flowQ2 2026-$1.92M
KPRX free cash flow was -$1.92M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.84M a year earlier. For the full fiscal 2025 it was -$10.07M, compared with $8.55M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $16.02M | $0 | - | $0 | $12.1K | $2.69M | $1.65M | $407.5K | $669.3K |
| Research and development | $10.78M | $7.84M | $4.03M | $3.45M | $5.35M | $3.57M | $5.39M | $8.06M | $10.33M | $8.42M |
| Selling, general and admin | $5.75M | $5.54M | $4.66M | $8.28M | $5.32M | $4.66M | $4.41M | $4.44M | $4.64M | $5.59M |
| Operating income | -$12.83M | $4.51M | -$12.59M | -$12.31M | -$14.24M | -$6.87M | - | -$10.84M | - | - |
| Interest expense | $20.0K | $21.4K | $11.1K | $8.6K | $6.9K | $4.2K | $325 | $1.0K | $1.2K | $275 |
| Pre-tax income | -$12.12M | $5.66M | -$12.42M | -$13.70M | -$13.96M | -$6.85M | -$7.00M | -$10.73M | -$14.56M | -$13.34M |
| Income tax | -$1.28M | $2.07M | $90.3K | -$113.0K | -$192.6K | $12.1K | $95.4K | $86.0K | -$1.34M | $0 |
| Net income | -$10.84M | $3.59M | -$12.51M | -$13.58M | -$13.77M | -$6.86M | -$7.10M | -$10.81M | -$13.22M | -$13.34M |
| EPS, basic | -$2.60 | $0.93 | -$24.25 | -$18.55 | -$57.12 | -$59.60 | -$89.20 | -$182.80 | -$558.00 | -$906.00 |
| EPS, diluted | -$2.64 | $0.87 | -$24.25 | -$18.55 | -$57.12 | -$59.60 | -$89.20 | -$182.80 | -$558.00 | -$906.00 |
| Diluted shares | 4.1M | 4.1M | 538,007 | 732,303 | 241,099 | 114,787.275 | 79,525.475 | 59,139.575 | 23,766.838 | 14,723.163 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.70M | $3.80M | $2.46M | $6.01M | $7.90M | $1.23M | $3.82M | $8.05M | $7.85M | $3.68M |
| Short-term investments | $8.39M | $23.00M | $0 | - | - | - | - | - | - | - |
| Receivables | $1.52M | $601.2K | $0 | - | - | - | - | - | - | - |
| Current assets | $21.75M | $29.71M | $4.74M | $7.68M | $8.99M | $1.73M | $4.32M | $8.48M | $8.46M | $4.15M |
| Goodwill | - | - | - | $0 | $0 | $3.63M | $1.53M | $1.53M | $1.53M | - |
| Total assets | $24.25M | $36.48M | $13.71M | $18.68M | $20.13M | $15.30M | $10.11M | $14.28M | $14.31M | $9.73M |
| Current liabilities | $3.63M | $6.01M | $1.63M | $3.27M | $1.61M | $1.98M | $1.41M | $3.86M | $14.83M | $7.31M |
| Long-term debt | - | - | - | - | - | $278.2K | $0 | - | - | - |
| Total debt | - | - | - | - | - | $278.2K | $0 | - | - | - |
| Total liabilities | $8.13M | $10.72M | $7.60M | $7.27M | $5.55M | $5.57M | $3.49M | $5.34M | $16.23M | $10.06M |
| Shareholders' equity | $16.13M | $25.76M | $6.11M | $11.41M | $14.58M | $9.73M | $6.62M | $8.94M | -$1.93M | -$329.4K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.96M | $8.56M | -$9.56M | -$10.43M | -$10.68M | -$7.32M | -$8.15M | -$10.84M | -$6.47M | -$8.41M |
| Capital expenditures | $110.8K | $6.3K | $0 | $0 | $63.9K | $20.1K | $0 | $20.0K | $37.0K | $0 |
| Free cash flow | -$10.07M | $8.55M | -$9.56M | -$10.43M | -$10.74M | -$7.34M | -$8.15M | -$10.86M | -$6.51M | -$8.41M |
| Investing cash flow | $14.43M | -$22.66M | $0 | $6.4K | -$157.0K | -$244.4K | $0 | -$270.0K | -$37.0K | $174.7K |
| Financing cash flow | $265.7K | $15.50M | $5.97M | $8.62M | $17.58M | $5.00M | $3.92M | $11.30M | $10.67M | $3.50M |
| Stock-based compensation | $900.2K | $656.6K | $754.9K | $462.4K | $842.5K | $723.9K | $852.2K | $875.3K | $870.3K | $511.0K |
| Depreciation and amortization | $24.8K | $19.2K | $51.8K | $41.6K | $45.3K | $33.4K | $51.7K | $38.5K | $19.3K | $5.2K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | - | - | - | -100.0% | -99.6% | 62.5% | 305.5% | -39.1% | - |
| Operating margin | - | 28.2% | - | - | - | -56960.5% | - | -656.3% | - | - |
| Net margin | - | 22.4% | - | - | - | -56901.7% | -264.2% | -654.2% | -3243.5% | -1993.8% |
| Free cash flow margin | - | 53.4% | - | - | - | -60844.6% | -303.6% | -657.5% | -1596.4% | -1257.1% |
| Return on equity | -67.2% | 14.0% | -204.8% | -119.1% | -94.5% | -70.5% | -107.2% | -121.0% | - | - |
| Return on assets | -44.7% | 9.9% | -91.3% | -72.7% | -68.4% | -44.8% | -70.2% | -75.7% | -92.4% | -137.1% |
| Current ratio | 5.99 | 4.94 | 2.90 | 2.35 | 5.59 | 0.87 | 3.06 | 2.19 | 0.57 | 0.57 |
| Debt to equity | - | - | - | - | - | 0.03 | 0.00 | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $20.0K | $16.00M | $0 | $0 |
| Research and development | $2.08M | $2.12M | $2.93M | $2.73M | $2.59M | $2.53M | $1.92M | $2.18M | $2.05M | $1.68M | $1.11M | $1.09M |
| Selling, general and admin | $1.38M | $1.61M | $1.46M | $1.44M | $1.35M | $1.49M | $1.33M | $1.38M | $1.54M | $1.30M | $880.5K | $1.42M |
| Operating income | -$2.21M | -$2.51M | -$7.31M | -$794.4K | -$2.40M | -$2.33M | -$2.56M | -$3.60M | -$2.54M | $13.22M | -$2.12M | -$5.92M |
| Pre-tax income | -$2.08M | -$2.42M | -$7.17M | -$616.3K | -$2.26M | -$2.07M | -$2.16M | -$3.41M | -$2.22M | $13.45M | - | - |
| Income tax | $0 | $0 | -$650.0K | -$643.1K | -$112.1K | $123.0K | $2.07M | $0 | $0 | $0 | - | - |
| Net income | -$2.08M | -$2.42M | -$6.52M | $26.8K | -$2.15M | -$2.19M | -$4.22M | -$3.41M | -$2.22M | $13.45M | -$2.27M | -$5.76M |
| EPS, basic | -$0.34 | -$0.58 | -$1.55 | $0.01 | -$0.54 | -$0.52 | -$2.40 | -$0.81 | -$0.53 | $4.67 | - | -$7.30 |
| EPS, diluted | -$0.34 | -$0.58 | -$1.59 | $0.01 | -$0.54 | -$0.52 | -$1.25 | -$0.81 | -$0.53 | $3.46 | - | -$7.30 |
| Diluted shares | 6.2M | 4.2M | - | 4.4M | 4.0M | 4.2M | - | 4.2M | 4.2M | 3.9M | - | 789,656 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.08M | $10.96M | $8.70M | $5.51M | $1.03M | $3.78M | $3.80M | $5.64M | $6.58M | $31.28M | $2.46M | $5.40M |
| Short-term investments | $9.76M | $2.92M | $8.39M | $13.87M | $19.64M | $20.33M | $23.00M | $23.40M | $21.24M | - | $0 | - |
| Receivables | $1.09M | $1.54M | $1.52M | $1.21M | $2.42M | $1.34M | $601.2K | $1.78M | $1.34M | $189.9K | $0 | - |
| Current assets | $21.26M | $18.68M | $21.75M | $22.69M | $24.74M | $27.11M | $29.71M | $31.65M | $31.83M | $33.48M | $4.74M | $6.98M |
| Total assets | $23.78M | $21.23M | $24.25M | $29.86M | $31.95M | $34.02M | $36.48M | $38.51M | $40.81M | $42.44M | $13.71M | $15.90M |
| Current liabilities | $2.37M | $2.80M | $3.63M | $2.58M | $3.19M | $5.27M | $6.01M | $3.53M | $1.66M | $1.59M | $1.63M | $2.10M |
| Total liabilities | $6.92M | $7.29M | $8.13M | $7.45M | $9.82M | $10.32M | $10.72M | $8.48M | $7.71M | $7.54M | $7.60M | $7.79M |
| Shareholders' equity | $16.86M | $13.93M | $16.13M | $22.41M | $22.13M | $23.70M | $25.76M | $30.03M | $33.10M | $34.90M | $6.11M | $8.10M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.89M | -$3.16M | -$2.18M | -$1.27M | -$3.80M | -$2.70M | -$2.25M | $920.1K | -$3.73M | $13.62M | -$2.58M | -$2.52M |
| Capital expenditures | $23.5K | $5.0K | $78.2K | $431 | $32.2K | $0 | -$45.0K | $0 | - | - | $0 | $0 |
| Free cash flow | -$1.92M | -$3.17M | -$2.26M | -$1.27M | -$3.84M | -$2.70M | -$2.30M | $920.1K | - | - | -$2.58M | -$2.52M |
| Investing cash flow | -$6.89M | $5.40M | $5.35M | $5.74M | $664.2K | $2.67M | $482.7K | -$1.92M | -$21.22M | $0 | $0 | $0 |
| Financing cash flow | $4.92M | -$842 | $296 | $0 | $265.4K | $0 | $0 | $0 | $250.5K | $15.25M | -$486.4K | $0 |
| Stock-based compensation | $109.3K | $209.5K | $234.4K | $254.4K | $262.8K | $148.6K | $160.2K | $171.2K | $149.8K | $175.4K | $182.3K | $264.9K |
| Depreciation and amortization | $10.7K | $10.6K | $10.5K | $10.6K | $3.4K | $318 | $5.9K | $2.1K | $6.3K | $4.9K | $7.9K | $11.3K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | -100.0% | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | -12724.4% | 82.6% | - | - |
| Net margin | - | - | - | - | - | - | - | - | -11108.2% | 84.1% | - | - |
| Current ratio | 8.97 | 6.68 | 5.99 | 8.79 | 7.76 | 5.14 | 4.94 | 8.97 | 19.22 | 21.02 | 2.90 | 3.32 |
Source: XBRL data Kiora Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Nov 7, 2019; 1-for-40, first reported Nov 9, 2022.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
KPRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KPRX | $0 | -100.0% | -$10.84M | - | $6.1M |
| OCUL | $50.38M | -9.7% | -$326.81M | -648.6% | $1.45B |
| HROW | $303.25M | +21.3% | -$28.49M | -9.4% | $1.14B |
| KALA | $0 | - | -$26.98M | - | $3.2M |
| OTLK | $1.41M | - | -$62.42M | -4416.2% | $111.8M |
KPRX FAQ
8 questionsWhat is KPRX revenue?
Kiora Pharmaceuticals Inc. (KPRX) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is KPRX profitable?
No. Kiora Pharmaceuticals Inc. reported a net loss of $10.84M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does KPRX have?
Kiora Pharmaceuticals Inc. reported $7.08M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is KPRX revenue growing?
Kiora Pharmaceuticals Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is KPRX free cash flow?
Kiora Pharmaceuticals Inc. generated -$10.07M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$9.96M less capital expenditures.What is KPRX earnings per share?
Diluted earnings per share were -$2.64 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did KPRX last report financial results?
The latest statements here come from Kiora Pharmaceuticals Inc.'s 10-Q filed on Aug 7, 2026, covering the period ended Jun 30, 2026.Where does this KPRX financial data come from?
Quantisnow builds these statements from the structured XBRL data Kiora Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.